Published in Mol Cell on December 22, 2005
Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell (2010) 17.48
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature (2010) 15.63
Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta (2006) 7.33
Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. Cancer Res (2008) 6.05
A dimerization-dependent mechanism drives RAF catalytic activation. Nature (2009) 5.39
PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells. Pigment Cell Melanoma Res (2010) 4.50
The 14-3-3 proteins: integrators of diverse signaling cues that impact cell fate and cancer development. Trends Cell Biol (2008) 3.30
Vemurafenib: the first drug approved for BRAF-mutant cancer. Nat Rev Drug Discov (2012) 3.09
Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. Aging (Albany NY) (2011) 2.72
Melanoma: from mutations to medicine. Genes Dev (2012) 2.59
Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond. Nat Rev Cancer (2014) 2.54
Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy. Expert Opin Ther Targets (2012) 2.42
CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations. Oncogene (2008) 2.19
Distinct requirement for an intact dimer interface in wild-type, V600E and kinase-dead B-Raf signalling. EMBO J (2012) 2.09
The role of BRAF V600 mutation in melanoma. J Transl Med (2012) 2.00
Regulation of MAPKs by growth factors and receptor tyrosine kinases. Biochim Biophys Acta (2007) 1.97
Role of mTOR in anticancer drug resistance: perspectives for improved drug treatment. Drug Resist Updat (2008) 1.90
Impact of feedback phosphorylation and Raf heterodimerization on normal and mutant B-Raf signaling. Mol Cell Biol (2009) 1.81
Targeting the mitogen-activated protein kinase pathway: physiological feedback and drug response. Clin Cancer Res (2010) 1.77
Paradoxical oncogenesis--the long-term effects of BRAF inhibition in melanoma. Nat Rev Clin Oncol (2013) 1.77
Raf family kinases: old dogs have learned new tricks. Genes Cancer (2011) 1.72
Disruption of angiogenesis and tumor growth with an orally active drug that stabilizes the inactive state of PDGFRbeta/B-RAF. Proc Natl Acad Sci U S A (2010) 1.67
Allosteric activation of functionally asymmetric RAF kinase dimers. Cell (2013) 1.60
Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers. Nature (2013) 1.52
Regulation of ERK1/2 by ouabain and Na-K-ATPase-dependent energy utilization and AMPK activation in parotid acinar cells. Am J Physiol Cell Physiol (2008) 1.49
A Mek1-Mek2 heterodimer determines the strength and duration of the Erk signal. Nat Struct Mol Biol (2009) 1.48
Characterization of Ser338 phosphorylation for Raf-1 activation. J Biol Chem (2008) 1.48
Selective Raf inhibition in cancer therapy. Expert Opin Ther Targets (2007) 1.44
Mutation that blocks ATP binding creates a pseudokinase stabilizing the scaffolding function of kinase suppressor of Ras, CRAF and BRAF. Proc Natl Acad Sci U S A (2011) 1.44
Impact of BRAF mutation status in the prognosis of cutaneous melanoma: an area of ongoing research. Ann Transl Med (2015) 1.42
Effects of Raf dimerization and its inhibition on normal and disease-associated Raf signaling. Mol Cell (2013) 1.37
Constitutive activation of Raf-1 induces glioma formation in mice. Neoplasia (2008) 1.36
14-3-3 Proteins: diverse functions in cell proliferation and cancer progression. Semin Cell Dev Biol (2011) 1.31
Growth-inhibitory and antiangiogenic activity of the MEK inhibitor PD0325901 in malignant melanoma with or without BRAF mutations. Neoplasia (2009) 1.23
Sequence analysis of 515 kinase genes in chronic lymphocytic leukemia. Leukemia (2011) 1.18
Exome sequencing of desmoplastic melanoma identifies recurrent NFKBIE promoter mutations and diverse activating mutations in the MAPK pathway. Nat Genet (2015) 1.15
Essential role of B-Raf in oligodendrocyte maturation and myelination during postnatal central nervous system development. J Cell Biol (2008) 1.14
Kinase-activating and kinase-impaired cardio-facio-cutaneous syndrome alleles have activity during zebrafish development and are sensitive to small molecule inhibitors. Hum Mol Genet (2009) 1.13
The secret life of kinases: functions beyond catalysis. Cell Commun Signal (2011) 1.13
Kinases and pseudokinases: lessons from RAF. Mol Cell Biol (2014) 1.10
Inhibitors that stabilize a closed RAF kinase domain conformation induce dimerization. Nat Chem Biol (2013) 1.10
RAF265 inhibits the growth of advanced human melanoma tumors. Clin Cancer Res (2012) 1.09
Overcoming resistance to molecularly targeted anticancer therapies: Rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignancies. Drug Resist Updat (2007) 1.08
Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanoma. J Invest Dermatol (2014) 1.07
BRAF inactivation drives aneuploidy by deregulating CRAF. Cancer Res (2010) 1.05
Genetic and biochemical alterations in non-small cell lung cancer. Biochem Res Int (2012) 1.05
Diacylglycerol kinase eta augments C-Raf activity and B-Raf/C-Raf heterodimerization. J Biol Chem (2009) 1.03
New strategies in melanoma: molecular testing in advanced disease. Clin Cancer Res (2012) 1.01
N terminus of ASPP2 binds to Ras and enhances Ras/Raf/MEK/ERK activation to promote oncogene-induced senescence. Proc Natl Acad Sci U S A (2012) 1.00
Targeting the RAS pathway in melanoma. Trends Mol Med (2011) 0.98
Mammalian Ste20-like kinase (Mst2) indirectly supports Raf-1/ERK pathway activity via maintenance of protein phosphatase-2A catalytic subunit levels and consequent suppression of inhibitory Raf-1 phosphorylation. J Biol Chem (2010) 0.98
Clinical detection and categorization of uncommon and concomitant mutations involving BRAF. BMC Cancer (2015) 0.98
Mechanism and consequences of RAF kinase activation by small-molecule inhibitors. Br J Cancer (2014) 0.97
Signal control through Raf: in sickness and in health. Cell Res (2011) 0.97
Single substitution within the RKTR motif impairs kinase activity but promotes dimerization of RAF kinase. J Biol Chem (2011) 0.97
Sorafenib: complexities of Raf-dependent and Raf-independent signaling are now unveiled. Med Mol Morphol (2011) 0.97
p16INK4a expression and absence of activated B-RAF are independent predictors of chemosensitivity in melanoma tumors. Neoplasia (2008) 0.96
BRAF(V600E) efficient transformation and induction of microsatellite instability versus KRAS(G12V) induction of senescence markers in human colon cancer cells. Neoplasia (2009) 0.94
Dimerization in protein kinase signaling. J Biol (2006) 0.93
The amino-terminal B-Raf-specific region mediates calcium-dependent homo- and hetero-dimerization of Raf. EMBO J (2006) 0.93
Dimerization is essential for 14-3-3zeta stability and function in vivo. J Biol Chem (2009) 0.92
DYRK1A autophosphorylation on serine residue 520 modulates its kinase activity via 14-3-3 binding. Mol Biol Cell (2007) 0.92
"RAF" neighborhood: protein-protein interaction in the Raf/Mek/Erk pathway. FEBS Lett (2014) 0.91
C-RAF mutations confer resistance to RAF inhibitors. Cancer Res (2013) 0.91
Vemurafenib: a new treatment for BRAF-V600 mutated advanced melanoma. Cancer Manag Res (2012) 0.91
Targeted inhibition of BRAF kinase: opportunities and challenges for therapeutics in melanoma. Biosci Rep (2012) 0.90
Targeted therapy for melanoma: a primer. Surg Oncol Clin N Am (2011) 0.89
Differential regulation of B-raf isoforms by phosphorylation and autoinhibitory mechanisms. Mol Cell Biol (2006) 0.89
The importance of Raf dimerization in cell signaling. Small GTPases (2013) 0.88
Ablation of BRaf impairs neuronal differentiation in the postnatal hippocampus and cerebellum. PLoS One (2013) 0.88
Increased BRAF heterodimerization is the common pathogenic mechanism for noonan syndrome-associated RAF1 mutants. Mol Cell Biol (2012) 0.87
Inhibiting MEK in MAPK pathway-activated myeloma. Leukemia (2015) 0.87
IκB kinase-induced interaction of TPL-2 kinase with 14-3-3 is essential for Toll-like receptor activation of ERK-1 and -2 MAP kinases. Proc Natl Acad Sci U S A (2014) 0.85
Understanding the biology of melanoma and therapeutic implications. Hematol Oncol Clin North Am (2014) 0.85
Review of histopathological and molecular prognostic features in colorectal cancer. Cancers (Basel) (2011) 0.85
Mechanism of RAF isoform switching induced by oncogenic RAS in melanoma. Small GTPases (2011) 0.85
Structural Basis for the Non-catalytic Functions of Protein Kinases. Structure (2016) 0.84
Hierarchical scaffolding of an ERK1/2 activation pathway. Cell Commun Signal (2013) 0.84
Signaling threshold regulation by the Ras effector IMP. J Biol Chem (2008) 0.84
Calcineurin increases glucose activation of ERK1/2 by reversing negative feedback. Proc Natl Acad Sci U S A (2010) 0.84
Cortical migration defects in mice expressing A-RAF from the B-RAF locus. Mol Cell Biol (2006) 0.84
Catalytic mechanisms and regulation of protein kinases. Methods Enzymol (2014) 0.83
Response regulator-mediated MAPKKK heteromer promotes stress signaling to the Spc1 MAPK in fission yeast. Mol Biol Cell (2013) 0.83
The Complexity of the ERK/MAP-Kinase Pathway and the Treatment of Melanoma Skin Cancer. Front Cell Dev Biol (2016) 0.83
Low BRAF and NRAS expression levels are associated with clinical benefit from DTIC therapy and prognosis in metastatic melanoma. Clin Exp Metastasis (2013) 0.82
BAD contributes to RAF-mediated proliferation and cooperates with B-RAF-V600E in cancer signaling. J Biol Chem (2011) 0.82
Valproic acid overcomes transforming growth factor-β-mediated sorafenib resistance in hepatocellular carcinoma. Int J Clin Exp Pathol (2014) 0.82
Topological analysis of MAPK cascade for kinetic ErbB signaling. PLoS One (2008) 0.82
ERK crosstalks with 4EBP1 to activate cyclin D1 translation during quinol-thioether-induced tuberous sclerosis renal cell carcinoma. Toxicol Sci (2011) 0.81
IMP modulates KSR1-dependent multivalent complex formation to specify ERK1/2 pathway activation and response thresholds. J Biol Chem (2008) 0.81
Elimination of B-RAF in oncogenic C-RAF-expressing alveolar epithelial type II cells reduces MAPK signal intensity and lung tumor growth. J Biol Chem (2014) 0.81
Negative feedback regulation of the ERK1/2 MAPK pathway. Cell Mol Life Sci (2016) 0.81
Cancer: Melanoma troops massed. Nature (2009) 0.81
The dual RAF/MEK inhibitor CH5126766/RO5126766 may be a potential therapy for RAS-mutated tumor cells. PLoS One (2014) 0.81
Identification of testis 14-3-3 binding proteins by tandem affinity purification. Spermatogenesis (2011) 0.81
Truncated RAF kinases drive resistance to MET inhibition in MET-addicted cancer cells. Oncotarget (2015) 0.80
EBI-907, a novel BRAF(V600E) inhibitor, has potent oral anti-tumor activity and a broad kinase selectivity profile. Cancer Biol Ther (2016) 0.79
BRAF kinase domain mutations are present in a subset of chronic myelomonocytic leukemia with wild-type RAS. Am J Hematol (2014) 0.79
Complexity in KSR function revealed by Raf inhibitor and KSR structure studies. Small GTPases (2011) 0.79
Genotyping of cutaneous melanoma. Chin Clin Oncol (2014) 0.78
Mutations of the BRAF gene in human cancer. Nature (2002) 65.42
Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell (2004) 19.51
Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell (2010) 17.48
Melanoma biology and new targeted therapy. Nature (2007) 10.71
The RAF proteins take centre stage. Nat Rev Mol Cell Biol (2004) 8.04
RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med (2012) 6.93
Structural insights into mRNA recognition from a PIWI domain-siRNA guide complex. Nature (2005) 6.23
Rac activation and inactivation control plasticity of tumor cell movement. Cell (2008) 6.01
Guilty as charged: B-RAF is a human oncogene. Cancer Cell (2004) 4.97
Oncogenic Braf induces melanocyte senescence and melanoma in mice. Cancer Cell (2009) 4.76
Redox regulation of protein tyrosine phosphatase 1B involves a sulphenyl-amide intermediate. Nature (2003) 4.60
V599EB-RAF is an oncogene in melanocytes. Cancer Res (2004) 4.49
In melanoma, RAS mutations are accompanied by switching signaling from BRAF to CRAF and disrupted cyclic AMP signaling. Cancer Res (2006) 4.29
Oncogenic BRAF induces melanoma cell invasion by downregulating the cGMP-specific phosphodiesterase PDE5A. Cancer Cell (2011) 4.02
Gatekeeper mutations mediate resistance to BRAF-targeted therapies. Sci Transl Med (2010) 3.98
Molecular discrimination of structurally equivalent Lys 63-linked and linear polyubiquitin chains. EMBO Rep (2009) 3.94
Crystal structure of an activated Akt/protein kinase B ternary complex with GSK3-peptide and AMP-PNP. Nat Struct Biol (2002) 3.77
B-RAF is a therapeutic target in melanoma. Oncogene (2004) 3.61
Crystal structure of a PIWI protein suggests mechanisms for siRNA recognition and slicer activity. EMBO J (2004) 3.57
A family with severe insulin resistance and diabetes due to a mutation in AKT2. Science (2004) 3.54
Molecular mechanism for the regulation of protein kinase B/Akt by hydrophobic motif phosphorylation. Mol Cell (2002) 3.53
ROCK and JAK1 signaling cooperate to control actomyosin contractility in tumor cells and stroma. Cancer Cell (2011) 2.77
Structure of the mitotic checkpoint complex. Nature (2012) 2.72
PTPN11 (Shp2) mutations in LEOPARD syndrome have dominant negative, not activating, effects. J Biol Chem (2005) 2.68
Nilotinib and MEK inhibitors induce synthetic lethality through paradoxical activation of RAF in drug-resistant chronic myeloid leukemia. Cancer Cell (2011) 2.57
KSR2 mutations are associated with obesity, insulin resistance, and impaired cellular fuel oxidation. Cell (2013) 2.56
Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma. Cancer Discov (2012) 2.56
Identification of direct transcriptional targets of (V600E)BRAF/MEK signalling in melanoma. Pigment Cell Melanoma Res (2009) 2.42
New insight into BRAF mutations in cancer. Curr Opin Genet Dev (2007) 2.40
Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycin. Cancer Res (2005) 2.34
Molecular basis of AKAP specificity for PKA regulatory subunits. Mol Cell (2006) 2.33
Argonaute: A scaffold for the function of short regulatory RNAs. Trends Biochem Sci (2006) 2.28
Enhancement of the seed-target recognition step in RNA silencing by a PIWI/MID domain protein. Mol Cell (2009) 2.27
The structure of the CYLD USP domain explains its specificity for Lys63-linked polyubiquitin and reveals a B box module. Mol Cell (2008) 2.27
ERK-MAPK signaling opposes Rho-kinase to promote endothelial cell survival and sprouting during angiogenesis. Cancer Cell (2006) 2.20
Oncogenic BRAF regulates melanoma proliferation through the lineage specific factor MITF. PLoS One (2008) 2.15
Doc1 mediates the activity of the anaphase-promoting complex by contributing to substrate recognition. EMBO J (2003) 2.14
Structures of APC/C(Cdh1) with substrates identify Cdh1 and Apc10 as the D-box co-receptor. Nature (2010) 2.11
A Raf-induced allosteric transition of KSR stimulates phosphorylation of MEK. Nature (2011) 2.07
Effect of SMURF2 targeting on susceptibility to MEK inhibitors in melanoma. J Natl Cancer Inst (2012) 2.01
Novel inhibitors of B-RAF based on a disubstituted pyrazine scaffold. Generation of a nanomolar lead. J Med Chem (2006) 1.94
Structure of the A20 OTU domain and mechanistic insights into deubiquitination. Biochem J (2008) 1.94
Expression of endogenous oncogenic V600EB-raf induces proliferation and developmental defects in mice and transformation of primary fibroblasts. Cancer Res (2005) 1.93
Whole genome sequencing of matched primary and metastatic acral melanomas. Genome Res (2011) 1.90
Molecular basis for TPR domain-mediated regulation of protein phosphatase 5. EMBO J (2004) 1.86
Getting into position: the catalytic mechanisms of protein ubiquitylation. Biochem J (2004) 1.83
Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: a phase II study in a UK based population. Eur J Endocrinol (2011) 1.82
Thyrotrophin receptor signaling dependence of Braf-induced thyroid tumor initiation in mice. Proc Natl Acad Sci U S A (2011) 1.82
Crystal structure and functional analysis of the eukaryotic class II release factor eRF3 from S. pombe. Mol Cell (2004) 1.81
Structural basis for the subunit assembly of the anaphase-promoting complex. Nature (2011) 1.80
The structure of the 26S proteasome subunit Rpn2 reveals its PC repeat domain as a closed toroid of two concentric α-helical rings. Structure (2012) 1.78
BRAF signaling and targeted therapies in melanoma. Hematol Oncol Clin North Am (2009) 1.74
Mutations of C-RAF are rare in human cancer because C-RAF has a low basal kinase activity compared with B-RAF. Cancer Res (2005) 1.71
Elevated expression of MITF counteracts B-RAF-stimulated melanocyte and melanoma cell proliferation. J Cell Biol (2005) 1.66
Pyridoimidazolones as novel potent inhibitors of v-Raf murine sarcoma viral oncogene homologue B1 (BRAF). J Med Chem (2009) 1.65
Structural analysis of the anaphase-promoting complex reveals multiple active sites and insights into polyubiquitylation. Mol Cell (2005) 1.65
Intravital imaging reveals transient changes in pigment production and Brn2 expression during metastatic melanoma dissemination. Cancer Res (2009) 1.63
Functions and mechanisms of redox regulation of cysteine-based phosphatases. Antioxid Redox Signal (2005) 1.62
FGF-2 protects small cell lung cancer cells from apoptosis through a complex involving PKCepsilon, B-Raf and S6K2. EMBO J (2006) 1.61
Protein kinase A blocks Raf-1 activity by stimulating 14-3-3 binding and blocking Raf-1 interaction with Ras. J Biol Chem (2003) 1.58
Elucidating distinct roles for NF1 in melanomagenesis. Cancer Discov (2012) 1.53
The role of B-RAF in melanoma. Cancer Metastasis Rev (2005) 1.53
Tumor necrosis factor-alpha blocks apoptosis in melanoma cells when BRAF signaling is inhibited. Cancer Res (2007) 1.50
Ras subcellular localization defines extracellular signal-regulated kinase 1 and 2 substrate specificity through distinct utilization of scaffold proteins. Mol Cell Biol (2008) 1.50
The structure of the cell cycle protein Cdc14 reveals a proline-directed protein phosphatase. EMBO J (2003) 1.49
Molecular recognition via coupled folding and binding in a TPR domain. J Mol Biol (2005) 1.48
Activation of Rho GTPases by DOCK exchange factors is mediated by a nucleotide sensor. Science (2009) 1.47
BRAF inhibitors induce metastasis in RAS mutant or inhibitor-resistant melanoma cells by reactivating MEK and ERK signaling. Sci Signal (2014) 1.44
TAT-apoptin is efficiently delivered and induces apoptosis in cancer cells. Oncogene (2004) 1.41
V600EBraf induces gastrointestinal crypt senescence and promotes tumour progression through enhanced CpG methylation of p16INK4a. EMBO Mol Med (2010) 1.36
An alpha-helical extension of the ELMO1 pleckstrin homology domain mediates direct interaction to DOCK180 and is critical in Rac signaling. Mol Biol Cell (2008) 1.36
Conformation-sensing antibodies stabilize the oxidized form of PTP1B and inhibit its phosphatase activity. Cell (2011) 1.34
Metformin accelerates the growth of BRAF V600E-driven melanoma by upregulating VEGF-A. Cancer Discov (2012) 1.33
AKAP18 contains a phosphoesterase domain that binds AMP. J Mol Biol (2007) 1.31
Lining the pockets of kinases and phosphatases. Curr Opin Struct Biol (2006) 1.30
VE-Cadherin-mediated cell-cell interaction suppresses sprouting via signaling to MLC2 phosphorylation. Curr Biol (2009) 1.29
Mechanism of multi-site phosphorylation from a ROCK-I:RhoE complex structure. EMBO J (2008) 1.27
Metformin: a diabetes drug for cancer, or a cancer drug for diabetics? J Clin Oncol (2012) 1.27
Reversible oxidation of the membrane distal domain of receptor PTPalpha is mediated by a cyclic sulfenamide. Biochemistry (2007) 1.26
Interaction between the innate and adaptive immune systems is required to survive sepsis and control inflammation after injury. Shock (2003) 1.25
The Brn-2 transcription factor links activated BRAF to melanoma proliferation. Mol Cell Biol (2004) 1.24
Differential oxidation of protein-tyrosine phosphatases. J Biol Chem (2004) 1.24
Structure of TOR and its complex with KOG1. Mol Cell (2007) 1.23
Architecture and dynamics of an A-kinase anchoring protein 79 (AKAP79) signaling complex. Proc Natl Acad Sci U S A (2011) 1.23
Coactivator functions in a stoichiometric complex with anaphase-promoting complex/cyclosome to mediate substrate recognition. EMBO Rep (2005) 1.21
Insights into degron recognition by APC/C coactivators from the structure of an Acm1-Cdh1 complex. Mol Cell (2013) 1.21
A structural comparison of inhibitor binding to PKB, PKA and PKA-PKB chimera. J Mol Biol (2007) 1.20
14-3-3 antagonizes Ras-mediated Raf-1 recruitment to the plasma membrane to maintain signaling fidelity. Mol Cell Biol (2002) 1.20
Regulation of protein kinases in insulin, growth factor and Wnt signalling. Curr Opin Struct Biol (2002) 1.20
The APC/C subunit Cdc16/Cut9 is a contiguous tetratricopeptide repeat superhelix with a homo-dimer interface similar to Cdc27. EMBO J (2010) 1.19
Conformational diversity in the TPR domain-mediated interaction of protein phosphatase 5 with Hsp90. Structure (2006) 1.18
Regulation of A20 and other OTU deubiquitinases by reversible oxidation. Nat Commun (2013) 1.17